DeepMed Research

Ferric carboxymaltose

Generic Name: Ferric carboxymaltose

Brand Names: Injectafer

Drug Type: Small Molecule

CAS Number: 9007-72-1

Unique Ingredient Identifier: 6897GXD6OE

Background: Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.

Indication: Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy. It is also indicated in adult patients who have non-dialysis-dependent chronic kidney disease.

Associated Conditions: Iron Deficiency Anemia (IDA)

Clinical Trials

Polyglucoferron Compared to i.v. Ferric Carboxymaltose and Oral Iron Substitution in Preoperative Treatment of Iron Deficiency Anaemia in Patients

Phase 3

Withdrawn

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferrous Sulfate
Drug: Polyglucoferron
Drug: Ferric carboxymaltose

First Posted Date: 2019-09-12

Last Posted Date: 2024-08-28

Lead Sponsor: Dr. Frank Behrens

Registration Number: NCT04087993

Locations: 🇩🇪
Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital of Goethe-University, Frankfurt, Hessia, Germany

Intraoperative IV Iron on Postoperative Red Blood Cell Recovery

Phase 4

Conditions: Osteoarthritis, Hip

Interventions: Drug: control
Drug: Ferric carboxymaltose

First Posted Date: 2019-07-29

Last Posted Date: 2020-08-19

Lead Sponsor: Konkuk University Medical Center

Target Recruit Count: 46

Registration Number: NCT04035902

Iron in Patients With Cardiovascular Disease

Phase 3

Terminated

Conditions: Atrial Fibrillation
Cardiovascular Diseases
Anemia, Iron-deficiency
Acute Myocardial Infarction
Systolic Heart Failure

Interventions: Drug: Ferric carboxymaltose
Drug: Saline

First Posted Date: 2019-06-19

Last Posted Date: 2023-12-27

Lead Sponsor: Dr. med. Mahir Karakas

Target Recruit Count: 8

Registration Number: NCT03991000

Locations: 🇩🇪
University of Ulm, Ulm, Germany
🇩🇪
University of Berlin, Campus Benjamin-Franklin, Berlin, Germany
🇩🇪
University Heart Center Hamburg, Hamburg, Germany

Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia

Phase 3

Completed

Conditions: Iron-deficiency
Postpartum Anemia Nos

Interventions: Drug: Iron Isomaltoside
Drug: Ferrous sulphate
Drug: Iron Carboxymaltose

First Posted Date: 2019-05-21

Last Posted Date: 2022-06-27

Lead Sponsor: University Medical Centre Ljubljana

Target Recruit Count: 300

Registration Number: NCT03957057

Locations: 🇸🇮
UMC Ljubljana, Ljubljana, Slovenia

Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure

Phase 4

Conditions: Systolic Heart Failure
Cardiac Failure
Heart Failure, Systolic

Interventions: Drug: Ferric carboxymaltose

First Posted Date: 2019-03-12

Last Posted Date: 2019-07-12

Lead Sponsor: Hospital Moinhos de Vento

Target Recruit Count: 20

Registration Number: NCT03871699

Locations: 🇧🇷
Hospital Moinhos de Vento, Porto Alegre, RS, Brazil

Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)

Phase 3

Completed

Conditions: Ferropenic Anemia
Heart Failure With Normal Ejection Fraction

Interventions: Drug: Ferroglycine Sulfate
Other: Placebo
Drug: Sucrosomial Iron
Drug: Ferric carboxymaltose

First Posted Date: 2019-02-07

Last Posted Date: 2025-05-21

Lead Sponsor: Institut de Recerca Biomèdica de Lleida

Target Recruit Count: 72

Registration Number: NCT03833336

Locations: 🇪🇸
Hospital de Manises, Manises, Valencia, Spain
🇪🇸
Hospital Universitari Arnau de Vilanova, Lleida, Spain

Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency

Phase 3

Conditions: Iron Deficiency Anemia

Interventions: Drug: Polyglucoferron
Drug: Ferric carboxymaltose
Drug: Ferrous Sulfate

First Posted Date: 2019-01-28

Last Posted Date: 2021-11-11

Lead Sponsor: Dr. Frank Behrens

Target Recruit Count: 407

Registration Number: NCT03817957

Locations: 🇩🇪
Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital of Goethe-University, Frankfurt, Hessia, Germany

Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation

Phase 3

Completed

Conditions: Iron-deficiency
Transplant-Related Disorder

Interventions: Drug: Ferric carboxymaltose
Drug: Sodium chloride

First Posted Date: 2018-12-07

Last Posted Date: 2024-08-27

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 148

Registration Number: NCT03769441

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands

Effects of Ferinject® on Anemia and Transfusion Rates After Cardiac Surgery

Phase 4

Completed

Conditions: Anemia, Iron Deficiency

Interventions: Drug: Ferric carboxymaltose
Drug: Placebo

First Posted Date: 2018-11-30

Last Posted Date: 2021-10-11

Lead Sponsor: St Joseph University, Beirut, Lebanon

Target Recruit Count: 194

Registration Number: NCT03759964

Locations: 🇱🇧
Hotel Dieu de France Hospital, Beirut, Lebanon

Postoperative Replacement of Intraoperative Iron Losses

Phase 4

Completed

Conditions: Blood Loss Anemia

Interventions: Drug: Crystalloid
Drug: Ferric carboxymaltose

First Posted Date: 2018-09-21

Last Posted Date: 2025-02-04

Lead Sponsor: Kepler University Hospital

Target Recruit Count: 134

Registration Number: NCT03680456

Locations: 🇦🇹
Universitätsklinik für Anästhesie und Intensivmedizin, Linz, Austria

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy